Spravato (esketamine) is a nasal spray used for depression and was approved by the FDA in 2019. It is specifically for treatment-resistant depression, meaning depression symptoms that have not ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a ...

Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...

I’d squirt the spray into my nose, where it’d drip to the back of my throat. The taste was potent: The office kept a dish of ...

Now, the Food and Drug Administration (FDA) has expanded approval for Johnson & Johnson's nasal spray, Spravato, to be used as a standalone treatment for people with severe depression who haven't ...

Spravato (esketamine) is a prescription drug that’s approved to treat certain forms of depression. Esketamine comes as a nasal spray that you inhale. Specifically, Spravato is approved by the ...

The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression. Spravato is ...

Since Spravato is FDA-approved, it’s covered by most insurance companies. IV ketamine, on the other hand, is generally not ...

The Food and Drug Administration has approved a new nasal spray for the treatment of severe depression. On Tuesday, the government agency announced Spravato nasal spray, also known as esketamine ...

Although the data indicates Spravato (and, by extension esketamine) helps many patients with treatment-resistant depression, researchers still aren’t sure how it technically works. But with most ...

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...